Related Experiment Video
Updated: Aug 19, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Clinical pharmacokinetics of nucleoside antiretroviral agents
1Antiinfective Pharmacology Research Unit, University of Rhode Island College of Pharmacy, Roger Williams Medical Center, Providence 02908.
Abstract:
The rapid clinical evaluation of new drugs active against human immunodeficiency virus (HIV) requires that pharmacologic properties be carefully considered to determine optimal exposure profiles in patients. The published pharmacokinetic data for the nucleoside antiretroviral agents zidovudine, didanosine, zalcitabine, stavudine, and lamivudine show that administration of fixed doses of certain agents results in a considerable degree of between-patient variability in in vivo drug exposure. Pharmacologic treatment of HIV infection requires development of strategies for individualized adjustment of doses of certain agents with a high degree of interpatient variability.
Related Concept Videos
Pharmacokinetics: Overview
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Antiviral Nucleoside Inhibitors

